Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Published: November 2011 No. of Pages: 126 Price: $ 3500
GlobalData, the industry analysis specialist, has released its new report, “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018�. The report is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the global ADHD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ADHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimates that the global ADHD therapeutics market was valued at $3855.6m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7114.5m by 2018. Between 2005 and 2010, three drugs namely Daytrana (methylphenidate), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine) were approved in the US. The acceptance for Vyvanse was high in the US, in spite of its high treatment cost in comparison to that of existing drugs. Thus, high acceptance for Vyvanse has resulted in the significant growth of the market. In 2009, the authorized generic versions of Adderall XR (mixed amphetamine salt) were launched, due to which the US market declined. This has resulted in the decline in the global ADHD market in 2009. Between 2010 and 2018, the global ADHD market is expected to grow at a CAGR of 8%. The growth rate is similar across the US and European countries, but it is slightly high in Japan (18.4%). This difference across geographical markets exists because of the variation in the approval date for some of the drugs in the US, Europe and Japan. In the US, major nonstimulant therapies such as Vyvanse, Intuniv and Kapvay (clonidine hydrochloride) are already approved; whereas these drugs are not approved in Europe and Japan. The entry of Vyvanse and Intuniv in major European markets is expected in 2012 and 2014 respectively. Vyvanse, being a safer nonstimulant, its acceptance across Europe would be high and considered as growth driving factor for the European ADHD market. The other drugs which are expected to enter into the market during the forecast period such as NWP06, CM4612
and RIT124D have similar therapeutic mode of action as that of exiting drugs which will not impact the market significantly. During this forecast period, patents for various drugs such as Adderall XR, Daytrana, Concerta (methylphenidate), Strattera (atomoxetine) and Kapvay are set to expire. However, the losses due to expiry of these patents would be compensated by new drugs entering the market such as Vyvanse and Intuniv. Thus, the global ADHD market will show a steady growth from 2010 to 2018. Scope The report provides information on the key drivers and challenges of the ADHD market. Its scope includes - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ADHD market revenues data from 2005 to 2010, forecast for eight years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as norepinephrine-dopamine reuptake inhibitor, selective alpha2A-adrenergic receptor agonist, serotonin-norepinephrine-dopamine reuptake inhibitor, selective serotonin (5-HT1)-dopamine antagonist, serotonin (5-HT1A and 5-HT1B) receptor agonists, highly selective norepinephrine reuptake inhibitor (NRI), antagonist of alcohol-metabolic effects, dopamine partial agonist, alpha 4 beta 2 neuronal nicotinic receptor (NNR) agonists, dopamine antagonist, alpha7 NNR agonist., serotonin and norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitors (SSRIs), dopamine (D2) receptors and serotonin type 2 (5-HT2) receptor agonist, alpha 3 beta 2 and alpha 4 beta 2 NNR antagonist, histamine H3 receptor antagonist, selective alpha2A-adrenergic receptor agonist, histamine H3 autoreceptor antagonist, Îą-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor modulators, specific phosphodiesterase 1 (PDE1) inhibitor, dopamine uptake inhibitors and serotonin (5-HT6) receptor antagonist. - Analysis of the current and future competition in the global ADHD market. Key market players covered are Curemark LLC, Johnson & Johnson, Nextwave Pharmaceuticals, Novartis AG and Shire Plc. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ADHD therapeutics market. - Analysis of key recent licensing and partnership agreements in ADHD market. Reasons to buy The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global ADHD market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ADHD market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global ADHD market landscape? – Identify, understand and capitalize. 1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 7 1.2 List of Figures 9 2 Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics: Executive Summary 11 2.1 ADHD Therapeutics Market is Forecast to Show Steady Growth Until 2018 11 2.2 Shire Remains the Unchallenged Leader of the ADHD Market 12 2.3 Current Medications Partly serve the ADHD Therapeutics Market 13 2.4 Expected Launch of New Molecules will Intensify Competition in the ADHD Market 14 2.5 Adult ADHD Market Presents Opportunity 14 3 Attention Deficit Hyperactivity Disorder (ADHD): Introduction 15 3.1 Disease Overview 15 3.2 Epidemiology 16 3.2.1 Prevalence/Incidence 16 3.2.2 Quality of Life (Qol) 18 3.2.3 Pharmacoeconomic Burden: 19 3.3 Etiology and Pathophysiology 20 3.3.1 Genetic Causes 20 3.3.2 Environmental Causes 21 3.4 Signs and Symptoms 22 3.4.1 Symptoms for Inattention 22 3.4.2 Symptoms for Hyperactivity 22 3.4.3 Symptoms for Impulsivity 22 3.5 Diagnosis 23 3.5.1 Diagnostic Criteria for ADHD 24 3.5.2 Rating Scales Used for the Diagnosis: 26 3.6 Treatment and Management Options 30 3.6.1 Pharmacologic Treatment: 31
3.6.2 Behavioral therapy 32 3.7 Referral Pathway 33 3.8 GlobalData Pipeline Report Guidance 35 4 ADHD Therapeutics: Market Characterization 36 4.1 ADHD Therapeutics Market Size (2005–2010) – Global 36 4.2 ADHD Therapeutics Market Forecast (2010–2018) – Global 37 4.3 ADHD Therapeutics Market Size (2005–2010) – The US 39 4.4 ADHD Therapeutics Market Forecast (2010–2018) – The US 40 4.5 ADHD Therapeutics Market Size (2005–2010) – France 41 4.6 ADHD Therapeutics Market Forecast (2010–2018) – France 43 4.7 ADHD Therapeutics Market Size (2005–2010) – Germany 44 4.8 ADHD Therapeutics Market Forecast (2010–2018) – Germany 45 4.9 ADHD Therapeutics Market Size (2005–2010) – Italy 47 4.10 ADHD Therapeutics Market Forecast (2010–2018) – Italy 48 4.11 ADHD Therapeutics Market Size (2005–2010) – Spain 50 4.12 ADHD Therapeutics Market Forecast (2010–2018) – Spain 51 4.13 ADHD Therapeutics Market Size (2005–2010) – The UK 52 4.14 ADHD Therapeutics Market Forecast (2010–2018) – The UK 53 4.15 ADHD Therapeutics Market Size (2005–2010) – Japan 55 4.16 ADHD Therapeutics Market Forecast (2010–2018) – Japan 56 4.17 Drivers and Barriers for the ADHD Therapeutics Market 58 4.17.1 Drivers for the ADHD Therapeutics Market 58 4.17.2 Barriers for the ADHD Therapeutics Market 58 4.18 Opportunity and Unmet Need Analysis 60 4.19 Key Takeaway 62 5 ADHD Therapeutics: Competitive Assessment 63 5.1 Overview 63 5.2 Strategic Competitor Assessment 63 5.3 Product Profiles for the Major Marketed Products in the ADHD Therapeutics Market 64 5.3.1 Ritalin LA (methylphenidate hydrochloride long acting capsules) 64 5.3.2 Adderall XR (Mixed amphetamine salt) 65 5.3.3 Daytrana (methylphenidate transdermal system) 68 5.3.4 Vyvanse (lisdexamfetamine dimesylate) 70 5.3.5 Concerta (methylphenidate hydrochloride) 73 5.3.6 Strattera (atomoxetine hydrochloride) 76 5.3.7 Intuniv (guanfacine) 78 5.3.8 Kapvay (clonidine hydrochloride) 80 5.4 Key Takeaway 82 6 ADHD Therapeutics: Pipeline Assessment 83 6.1 Overview 83 6.2 Strategic Pipeline Assessment 83 6.3 ADHD Therapeutics Pipeline – Pipeline by Phases of Development 84 6.3.1 ADHD Therapeutics – Filed Pipeline 84 6.3.2 ADHD Therapeutics – Phase III Pipeline 84 6.3.3 ADHD Therapeutics – Phase II/III Pipeline 85 6.3.4 ADHD Therapeutics – Phase II Pipeline 85 6.3.5 ADHD Therapeutics – Phase I Pipeline 86 6.3.6 ADHD Therapeutics – Pre-Clinical Pipeline 86 6.3.7 Technology Trends Analytic Framework 87 6.4 ADHD Therapeutics Market –Clinical Pipeline by Mechanism of Action 89
6.5 ADHD Therapeutics – Promising Drugs under Clinical Development 90 6.6 Molecule Profile for Promising Drug Under Clinical Development 91 6.6.1 NWP06 91 6.6.2 CM-4612 91 6.6.3 RIT124D 91 6.6.4 JNS001 91 6.7 Key Takeaway 91 7 ADHD Therapeutics: Clinical Trials Mapping 92 7.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 92 7.2 Clinical Trials by Phase 93 7.3 Clinical Trials by Trial Status 95 7.4 Prominent Sponsors 96 7.5 Top Companies Participating in ADHD Therapeutics Clinical Trials 98 8 Strategic Assessment 100 8.1 Key Events Impacting the Future Market 100 8.2 ADHD Therapeutics: Implications for Future Market Competition 101 9 ADHD Therapeutics: Future Players 103 9.1 Introduction 103 9.2 Company Profiles 104 9.2.1 Curemark, LLC. 104 9.2.2 Johnson & Johnson 104 9.2.3 NextWave Pharmaceuticals 107 9.2.4 Novartis AG 108 9.2.5 Shire Plc. 110 9.2.6 Other Companies in the ADHD Therapeutics Market 112 10 ADHD Therapeutics: Licensing and Partnership Deals 116 11 ADHD Therapeutics: Appendix 119 11.1 Market Definitions 119 11.2 Abbreviations 119 11.3 Methodology 121 11.3.1 Coverage 121 11.3.2 Secondary Research 121 11.3.3 Forecasting 122 11.3.4 Primary Research 124 11.3.5 Expert Panel Validation 125 11.4 Contact Us 125 11.5 Disclaimer 125 11.6 Bibliography 126
About Us: ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports. Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689 Contact: Mr.Priyank 7557 Rambler road, Suite727,Dallas,TX75231 Tel: + 1 888 391 5441 E-mail: sales@reportsandreports.com http://www.reportsnreports.com Visit our Market Research Blog